• support@domain.tld
  • support@domain.tld
Facebook-f Instagram Twitter Linkedin-in
logo Research
Contact us
Welcome to Retina Research Center of Wisconsin

Advancing and Pursuing the Cures for Serious Retinal Diseases.

Leveraging our clinical networks and extensive experience, we strive to allow patients to locally participate in national clinical trials for new treatments of numerous retinal diseases.
ABOUT US
Book a Lab Visit
Learn About our History

Promoting Patient Outcomes

Founded in 2025, Retina Research Center of Wisconsin is the first retina-only clinical trial organization in Wisconsin.
Our History
Learn more

Our Sponsors

logo-simple
Ocular_Logo@2x
logo
Our Vision

Promotion of research in the clinical setting with the goal of developing new treatments for patients with retinal disease.

Our Mission

To disseminate information concerning retinal diseases to the medical and non-medical community through educational conferences, the publication of scientific research papers and training of medical personnel.

Our Motto

To provide care for individuals suffering from retinal disease without resources to pay for medical services.

Explore our Research

A Diversity of Inquiry

Multiple clinical trials for a variety of retinal conditions create a patient-centric experience.

Retina Research Center of Wisconsin seeks to create a wide offering of clinical trials to meet unmet demand for patients in Southeast Wisconsin.

Below is a list of current trial involvement. Contact us for more information about enrollment or referrals.
Computer-1.png
REVEAL Study

A Non-interventional, observational study to evaluate treatment patterns and safety of Avacincaptad Pegol (ACP/IZERVAY™) in routine clinical practice in patients with geographic atrophy secondary to Age-Related Macular Degeneration

Learn more
Cloning-Techniques-1.png
HELIOS-2

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Non-Proliferative Diabetic Retinopathy

Learn more
Biotech-1.png
NOVA-1

A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration (NOVA-1)

Learn more
Explore our Research

A Diversity of Inquiry

Multiple clinical trials for a variety of retinal conditions create a patient-centric experience.
Learn more
Computer-1.png
REVEAL Study

A Non-interventional, observational study to evaluate treatment patterns and safety of Avacincaptad Pegol (ACP/IZERVAY™) in routine clinical practice in patients with geographic atrophy secondary to Age-Related Macular Degeneration

Learn more
Cloning-Techniques-1.png
HELIOS-2

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Non-Proliferative Diabetic Retinopathy

Learn more
Biotech-1.png
NOVA-1

A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration (NOVA-1)

Learn more
Pills-1.png
Lorem ipsum dolo

Facilisi convallis luctus penatibus ex pulvinar nascetur orci

Montes tellus suscipit risus euismod vel himenaeos. Arcu gravida maecenas tristique donec aliquet.
Learn more
Genomic-Privacy-1.png
Lorem ipsum dolo

Facilisi convallis luctus penatibus ex pulvinar nascetur orci

Montes tellus suscipit risus euismod vel himenaeos. Arcu gravida maecenas tristique donec aliquet.
Learn more
Petri-Dish-1.png
Lorem ipsum dolo

Facilisi convallis luctus penatibus ex pulvinar nascetur orci

Montes tellus suscipit risus euismod vel himenaeos. Arcu gravida maecenas tristique donec aliquet.
Learn more
Why Choose Us

Empowering Discovery With Trusted Expertise

At senectus amet ridiculus lacinia massa maximus cras urna. Integer velit leo ac tincidunt egestas. Erat ante dis libero efficitur magna commodo mi aliquam elementum.
Accurate Results
Fermentum adipiscing nunc penatibus vehicula aenean
Accurate Results
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Global Standards
Fermentum adipiscing nunc penatibus vehicula aenean
Global Standards
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Advanced Technology
Fermentum adipiscing nunc penatibus vehicula aenean
Advanced Technology
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Dedicated Team
Fermentum adipiscing nunc penatibus vehicula aenean
Dedicated Team
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Scientific Integrity
Fermentum adipiscing nunc penatibus vehicula aenean
Scientific Integrity
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Ethical Research
Fermentum adipiscing nunc penatibus vehicula aenean
Ethical Research
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
Reliable Support
Fermentum adipiscing nunc penatibus vehicula aenean
Reliable Support
Scelerisque nunc malesuada potenti habitasse eu ultricies lacus tortor massa curae fermentum
Learn more
0 +

Project Done

0 K+

Member Active

0

Client Reviews

0 +

Years of Experience

Understand our Capabilities

Robust advanced updates for clinical trials.

Retina Research Center of Wisconsin continually invests in new equipment to enable clinical trial participation
40

Years of Ophthalmology Experience

Meet Our Team

Our team has extensive background in retina clinical research, care and surgery

Nicholas Tosi, M.D.

President and Founder

Lincoln Shaw, M.D.

Research Partner

Razek Coussa, M.D., FRCSC

Clinical Director

Kevin Elwood, M.D.,

Research Investigator

Svetoslava Raykova, O.D.

Lead Research Coordinator

Customer Support?

(888) 4000-2424

Over 40 Years of Ophthalmology Experience
Live Chat
Play Intro
Explore How Retina Research Center Transforms Research Into Results
Explore Project
common Questions

Explore Common Questions About Retina Research Center Services

Patients should join clinical trials for potential access to cutting-edge treatments, specialized care, and a chance to play an active role in their health, while also helping to advance medical knowledge, find cures, and contribute to better future care for others with similar conditions, often with close monitoring and potentially lower costs.
Clinical trials progress through phases to test a new treatment's safety and effectiveness, starting with Phase 1 (small group, safety/dosage), moving to Phase 2 (more patients, effectiveness/side effects), then Phase 3 (large scale, comparing to standard care for overall risk/benefit), and finally Phase 4 (post-market, long-term monitoring) to ensure new therapies are safe and work well for the public.
Promising retinal clinical trials focus on gene therapies, optogenetics, stem cells, and new therapeutic agents for inherited diseases (like RP, Usher, Choroideremia), age-related conditions (AMD, geographic atrophy), and vascular diseases (DR, DME, and RVO) using tools like AAV vectors, new drug delivery and/or novel therapeutics, retinal implants, RPE cell patches to restore sight by targeting genetic defects, replacing damaged cells, electrically stimulating remaining nerves, or treating novel mechanisms targeting various disease processes.

Our experienced team of physicians of over 40 years of ophthalmology experience, extensive retinal research history, along with a dedicated staff including other eyecare professionals, provides customized and tailored care for patients who are good candidates for meaningful clinical trials.